D E Adkins

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, School of Pharmacy, Richmond, VA 23298 0581, USA
    Transl Psychiatry 2:e129. 2012
  2. ncbi The influence of five monoamine genes on trajectories of depressive symptoms across adolescence and young adulthood
    DANIEL E ADKINS
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, McGuire Hall, Room 216A, 1112 East Clay Street, Richmond, VA 23298, USA
    Dev Psychopathol 24:267-85. 2012
  3. ncbi A statistical method for excluding non-variable CpG sites in high-throughput DNA methylation profiling
    Hailong Meng
    Altria Client Services, Research Development and Engineering, Richmond, VA 23219, USA
    BMC Bioinformatics 11:227. 2010
  4. ncbi Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23223, USA
    Mol Psychiatry 16:321-32. 2011
  5. ncbi Genome-wide association study of antipsychotic-induced QTc interval prolongation
    K Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Pharmacogenomics J 12:165-72. 2012
  6. ncbi Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
    S L Clark
    Center for Biomarker Research and Personalized Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0581, USA
    Psychol Med 42:1151-62. 2012
  7. ncbi Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics
    J L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    Mol Psychiatry 16:76-85. 2011

Collaborators

  • J L McClay
  • P F Sullivan
  • J M Hettema
  • K Aberg
  • S L Clark
  • E J C G van den Oord
  • Hailong Meng
  • R P Souza
  • Y Liu
  • T S Stroup
  • J Bukszar
  • Z Zhao
  • P Jia
  • J A Lieberman
  • D Perkins
  • Andrew R Joyce
  • Tapas K Sengupta
  • E Lenn Murrelle
  • Yankai Jia
  • Barbara K Zedler
  • Edwin J C G van den Oord
  • Guoya Li
  • Priyadarshi Basu

Detail Information

Publications7

  1. ncbi Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, School of Pharmacy, Richmond, VA 23298 0581, USA
    Transl Psychiatry 2:e129. 2012
    ..Although our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that potentially mediate adverse effects of antidepressant medications...
  2. ncbi The influence of five monoamine genes on trajectories of depressive symptoms across adolescence and young adulthood
    DANIEL E ADKINS
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, McGuire Hall, Room 216A, 1112 East Clay Street, Richmond, VA 23298, USA
    Dev Psychopathol 24:267-85. 2012
    ..These results demonstrate the value of combining dynamic developmental perspectives with statistical genetic methods to optimize the search for genetic influences on psychopathology across the life course...
  3. ncbi A statistical method for excluding non-variable CpG sites in high-throughput DNA methylation profiling
    Hailong Meng
    Altria Client Services, Research Development and Engineering, Richmond, VA 23219, USA
    BMC Bioinformatics 11:227. 2010
    ..Inclusion of these so-called "non-variable sites" will increase the risk of false discoveries and reduce statistical power to detect biologically relevant methylation markers...
  4. ncbi Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23223, USA
    Mol Psychiatry 16:321-32. 2011
    ..Although our findings require replication and functional validation, this study shows the potential of GWAS to discover genes and pathways that potentially mediate adverse effects of antipsychotic medication...
  5. ncbi Genome-wide association study of antipsychotic-induced QTc interval prolongation
    K Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Pharmacogenomics J 12:165-72. 2012
    ..However, some genes may also be unique for drug-induced prolongation. This study demonstrates the potential of GWAS to discover genes and pathways that mediate antipsychotic-induced QT prolongation...
  6. ncbi Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
    S L Clark
    Center for Biomarker Research and Personalized Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0581, USA
    Psychol Med 42:1151-62. 2012
    ..Understanding individual differences in susceptibility to antidepressant therapy side-effects is essential to optimize the treatment of depression...
  7. ncbi Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics
    J L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    Mol Psychiatry 16:76-85. 2011
    ..This study demonstrates the potential of genome-wide association studies to discover novel genes that mediate the effects of antipsychotics, which could eventually help to tailor drug treatment to schizophrenic patients...